ConductScience.org, home

Trial · NCT07897149

Personalized Weight-Bearing With Smart Crutch Tips After Surgery for Tibial Plateau Fractures

NCT07897149, Not applicable, Not yet recruiting, Comeback Mobility Inc

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Personalized Weight-Bearing With Smart Crutch Tips After Surgery for Tibial Plateau Fractures. Trials, record NCT07897149. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897149

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Personalized Weight-Bearing With Smart Crutch Tips After Surgery for Tibial Plateau Fractures
NCT number
NCT07897149
Status
Not yet recruiting
Phases
Not applicable
Enrollment
86 participants, estimated
Lead sponsor
Comeback Mobility Inc
Conditions
Tibial Plateau Fracture
Interventions
Crutch Tip Biofeedback System, Individualized FEA-Guided Postoperative Weight-Bearing, Usual-Care Postoperative Weight-Bearing
First posted
2026-10-27
Last updated
2026-10-27

Source ClinicalTrials.gov

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryTime to Sustained Independent Walking Without Walking AidsFrom plate fixation through 52 weeks
Time in days from plate fixation to the first day of walking without crutches, a cane, or another walking aid, with pain in the injured limb during walking of no more than 2 on a 0-10 visual analogue scale at the time of transition, and no return to walking aids for at least 7 consecutive days. The event date is the first day of the confirmed period, not the date of confirmation. An independent assessor blinded to treatment group allocation confirms that the criteria are met and verifies the event date using participant reports and supporting records. Device non-use alone does not establish the outcome.
SecondaryTime to Radiographic Confirmation of Complete Fracture UnionFrom plate fixation through 52 weeks
Time in days from plate fixation to the first radiographic examination confirming complete fracture union. Complete union is defined as disappearance of the fracture line due to filling with bone tissue and complete bone remodeling at the fracture site. Anteroposterior, lateral, and oblique radiographs are compared with previous images and assessed by two independent radiologists blinded to treatment group allocation. Disagreements are resolved by a third blinded radiologist. Partial union does not meet the endpoint. The event date is the date of the first examination confirming complete union.
SecondaryProportion of Participants With Radiographic Secondary Loss of Reduction by Week 16From the first postoperative radiographic examination through the week 16 assessment after plate fixation, inclusive.
Proportion of participants with secondary loss of reduction on radiographs compared with the first postoperative radiographic examination. Loss of reduction is defined as at least one of the following changes: an increase in articular surface depression of at least 2 mm; an increase in interfragmentary gap of at least 2 mm; an increase in tibial plateau width of at least 5 mm; or worsening of varus/valgus alignment or posterior tibial slope by at least 5 degrees. These thresholds refer to changes from the postoperative baseline, not absolute residual displacement. Radiographs are assessed independently by radiologists blinded to treatment group allocation. Each participant is counted once, regardless of the number of criteria met. Insufficient imaging without a confirmed positive finding is classified as indeterminate, not as absence of loss of reduction
SecondaryKnee Injury and Osteoarthritis Outcome Score (KOOS) Subscale ScoresAt weeks 8, 16, and 52 after plate fixation; additionally at weeks 12, 20, 26, and 39 if these conditional visits take place.
Patient-reported knee outcomes assessed using the five KOOS subscales: Pain, Other Symptoms, Activities of Daily Living, Sport and Recreation Function, and Knee-Related Quality of Life. Each subscale is scored separately from 0 to 100, with higher scores indicating fewer knee problems. No overall total score is calculated. Assessments are performed at all attended in-person follow-up visits. Weeks 8, 16, and 52 are the mandatory time points for comparison between groups. Assessments at conditional visits are analyzed accounting for cancellation of these visits after confirmed fracture union.
SecondaryKnee Function Assessed by the Rasmussen Clinical ScoreAt weeks 8, 16, and 52 after plate fixation; additionally at weeks 12, 20, 26, and 39 if these conditional visits take place.
Knee function assessed using the Rasmussen Clinical Score, covering pain, walking capacity, knee extension, range of motion, and knee stability. Higher scores indicate better knee function. Range of motion is measured with a goniometer. Weight-bearing tests are performed only when clinically safe. Assessments are conducted at all attended in-person follow-up visits, with weeks 8, 16, and 52 serving as the mandatory time points for comparison between groups.
SecondaryFear of Movement Assessed by the Tampa Scale of Kinesiophobia (TSK-17)Immediately after training at the week 3 visit (±7 days) and at week 8 after plate fixation.
Fear of movement assessed using the 17-item Tampa Scale of Kinesiophobia (TSK-17). Total scores range from 17 to 68, with higher scores indicating greater fear of movement or reinjury. The first assessment is conducted remotely immediately after participant training at the week 3 visit, and the assessment is repeated at week 8. The first assessment is a post-training measurement and is not considered a pre-intervention baseline.
SecondaryAdherence to Prescribed Weight-Bearing in the Individualized Rehabilitation GroupThroughout the physician-prescribed weight-bearing restriction period, up to 52 weeks after plate fixation; summarized overall and by postoperative week.
Percentage of technically valid recorded steps within the prescribed loading range in the individualized rehabilitation group. The analytical range is the prescribed target ±10 percentage points of body weight, with a lower limit of zero. Each step is compared with the prescription active at the time of recording. Only days with at least 20 technically valid steps and a known prescription are included. Adherence is calculated as 100 × valid steps within range / all valid steps on eligible days. It is summarized over the entire restriction period and separately by postoperative week. Higher percentages indicate greater adherence. Days with insufficient data are excluded, not assigned 0% or 100%. Participants without eligible data are classified as not evaluable. This outcome is not calculated in the usual-care group.
SecondaryProportion of Participants With Fixation FailureFrom informed consent through 52 weeks after plate fixation
Proportion of participants with implant breakage or deformation, or implant migration or loosening associated with loss of stability. Events are documented using available imaging and clinical assessments. The date, type of failure, diagnostic findings, and treatment are recorded. Fixation failure is assessed separately from secondary loss of fracture reduction. Each participant with at least one qualifying event is counted once, regardless of the number of fixation failure events.
SecondaryProportion of Participants With Confirmed Symptomatic Deep Vein ThrombosisFrom informed consent through 52 weeks after plate fixation.
Proportion of participants with symptomatic deep vein thrombosis confirmed by diagnostic imaging or another appropriate instrumental examination. Routine ultrasound screening for asymptomatic thrombosis is not performed. The date, diagnostic findings, and treatment of each confirmed event are recorded. Each participant with at least one confirmed symptomatic event is counted once, regardless of the number of events.
SecondaryProportion of Participants With Infectious ComplicationsFrom informed consent through 52 weeks after plate fixation.
Proportion of participants with at least one infectious complication related to the study fracture or its treatment, including deep infection. The date, infection site, diagnostic findings, and treatment are recorded. Each participant with at least one qualifying infection is counted once, regardless of the number of infectious events.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07897149

GET https://conductscience.org/api/trials/v1/NCT07897149/registered